Phase
Alumni
Sinntaxis
Sinntaxis is committed to discovering, developing and commercialising novel therapeutics that enhance recovery of brain functions afterstroke. The company has an established discovery platform for preclinical studies of stroke recovery.
Tomas Eriksson has more than 10 years’ experience as CEO and co-founder of A1M Pharma, and 20+ years of experience in international marketing and sales, primarily within medical technology and diagnostics. He has also been involved in a number of early stage projects in life science, with a focus on business development and financing.
Did you know?
The Sinntaxis approach has shown improved restoration of brain function, enhancing the speed and extent of recovery after stroke.
Excellence in solid material analysis
Amplify the efficacy of pharmaceutical treatments
Simplify medicine information through digital services
A "check-in buddy" for the elderly
Excellence in inhaler performance
Behavioral coaching app
Antibiotic-free treatment for vaginal bacterial infections
Digital tool for meeting an allergy doctor
Cutting-Edge Histological Solutions for Pharma Industry
Digital communication tool for titrating medicine
Mobile systems for movement analysis
Innovative solutions for better health care
GPS tracker system for elderly
Drug delivery platform
Healthtech for children with eating challenges
Digital health management tool
Short chain fatty acids can be delivered to the colon
Therapeutics after stroke
Starch pickering emulsion technology
Measuring thyroid hormone levels
Gene editing analysis solution
Cost-effective & rapid COVID-19 diagnostic test
eHealth clinic for obesity treatment
